Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

• Main Authors: Lee, Hyeun Joung, Park, Kyungjin, Yeom, Donghoon, Yoo, Jiseon, Ahn, Jinhyung, Eom, Jaehyun, Kim, Hyoung Rae, Kim, Yong Zu, Sung, Byungje, Kim, Juhee, Lee, Yangsoon, Chae, Jeiwook, Ryu, Hyun Min, Baek, Ju Yuel, Park, Kyung Eun, Lee, Ju Young, Lee, Bora, Yang, Young-Jae, Han, Nara, Kim, Sung Min, Hong, Youngeun, Kang, Dae Hyuck, Park, Yun-Hee, Jung, Jinwon, Oh, Ji Hye, Lee, Chang Sun, You, Ji-Na, Song, Daehae, Park, Minji, Song, Ho Young
• Format: Patent
• Language: English
• Published: 25.07.2023
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.